Trial · NCT04776499
Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers
NCT04776499, Phase 1, Completed, Maastricht University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers. Trials, record NCT04776499. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04776499
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers
- NCT number
- NCT04776499
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 8 participants, actual
- Lead sponsor
- Maastricht University
- Conditions
- Drug Drug Interaction, Safety Issues
- Interventions
- Propylthiouracil, Riociguat, Perphenazine
- First posted
- 2021-03-01
- Last updated
- 2022-04-04
- Other registries' IDs
- eudract:2020-004557-73
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of blood pressure in supine position | 0.25, 0.5, 0.75, 1.0, 1.5, 2, 3 and 4 hours after drug administration compared to baseline (measured in triplicate 1-2 minutes apart) | Change of blood pressure in supine position (individual baseline compared to changes after propylthiouracil, riociguat, and perphenazine). Analysis of the primary endpoint will be done in the complete case set. Systolic and diastolic blood pressure (in supine position for ≥ 5 minutes). |
| Secondary | Time-course of blood pressure | Blood pressure at 0.25, 0.5, 0.75, 1.0, 1.5, 2, 3, 4, 8, and 24 hours after drug administration compared to baseline | Time-course of blood pressure after drug administration in supine position for up to 24 hours |
| Secondary | Pathological provocation test (tilt table) | Trial day 1 and 2 | Pathological provocation test (tilt table) at anticipated Cmax, as compared to baseline. Response to upright position of (pre)syncope, systolic / diastolic blood pressure decreases of \> 20 mmHg / 10 mmHg, or heart rate increase of \> 30 bpm in post dose tilt test. Difference between lowest systolic blood pressure in tilt test (70°) |
| Secondary | Change of heart rate variability | Trial day 1 and 2 | Change of heart rate variability (individual baseline compared to post dose propylthiouracil, riociguat, and perphenazine). Difference between highest heart rate in tilt test (70° position) and mean heart rate at baseline compared to post dose. Heart rate variability after drug administration compared to baseline (Holter ECG). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04776499
GET https://conductscience.org/api/trials/v1/NCT04776499/registered